We can’t show the full text here under this license. Use the link below to read it at the source.
Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
Comparing Two Diabetes Treatments: GLP-1 Receptor Agonists and SGLT2 Inhibitors for Type 2 Diabetes
AI simplified
Abstract
A meta-analysis of 85,219 subjects indicates that glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) similarly reduce (MACE) and cardiovascular deaths (CVD).
- Both GLP-1 RA and SGLT2i are associated with reductions in MACE and CVD compared to controls, with no significant preference for either class.
- SGLT2i significantly reduce (HHF), while GLP-1 RA do not show a similar benefit.
- Both drug classes demonstrate reductions in renal outcomes, but neither shows a preferential difference in effectiveness.
- Serious adverse events related to SGLT2i include mycotic genital infections and diabetic ketoacidosis, while gastrointestinal intolerance is noted for GLP-1 RA.
- Meta-regression suggests that the benefits of SGLT2i on CVD and HHF may be greater in populations with higher underlying rates of MACE.
AI simplified
Key numbers
51 762
Subjects in GLP-1 RA Trials
Total number of subjects across six major GLP-1 RA trials.
33 457
Subjects in SGLT2i Trials
Total number of subjects across four major SGLT2i trials.
0.68
Decrease in
Relative rate for with SGLT2i.